STOCK TITAN

Coya Therapeutics, Inc. - COYA STOCK NEWS

Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.

Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company advancing novel therapies that modulate regulatory T cells (Tregs) to treat neurodegenerative, autoimmune, and metabolic disorders. This page serves as the definitive source for official updates and analysis on COYA's progress in developing innovative immunology solutions.

Investors and researchers will find timely updates on clinical trial milestones, regulatory developments, and strategic collaborations. Our curated news collection includes verified information on therapy pipeline advancements, intellectual property updates, and financial disclosures essential for evaluating this innovative biotech company.

Key content focuses on COYA's multi-modality Treg platform developments, partnership announcements with research institutions, and progress toward addressing high-need conditions like ALS and Alzheimer's disease. All materials maintain journalistic rigor while avoiding speculative commentary.

Bookmark this page for structured access to COYA's latest scientific advancements and corporate developments. Check regularly for updates on this pioneering company's efforts to translate Treg research into transformative therapies.

Rhea-AI Summary

Coya Therapeutics (NASDAQ: COYA) announces promising results for COYA 302, a subcutaneously administered anti-inflammatory biologic, in a preclinical Parkinson's disease (PD) mouse model. The study shows that COYA 302 significantly reduces neuroinflammation in key brain regions affected by PD, including:

  • Decreased microglial activation in the nigrostriatal pathway
  • Reduced astrocyte numbers and activation (astrogliosis)

These findings suggest that COYA 302 can directly modulate brain inflammation when administered peripherally, potentially offering a new therapeutic approach for PD and other neurodegenerative diseases like Alzheimer's and Frontotemporal Dementia. The company plans to present or publish these results in a peer-reviewed setting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
Rhea-AI Summary

Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on enhancing regulatory T cell function, announces CEO Howard Berman's participation in two upcoming healthcare conferences. On September 26, 2024, Dr. Berman will join a panel discussion at Munsch Hardt's 3rd Annual Texas Health Care Transactions Conference in Houston. On October 28, 2024, Dr. Berman and Dr. Stanley Appel will present data on COYA 302 at the inaugural Alzheimer's Drug Discovery Foundation (ADDF) Summit in Madrid, Spain.

The company will also present results from a Gates Foundation and Alzheimer's Association funded study on low-dose interleukin-2 in Alzheimer's patients at the Clinical Trials on Alzheimer's Disease conference. In May 2024, Coya received a $5 million strategic equity investment from ADDF to support COYA 302's development for Frontotemporal Dementia treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences
-
Rhea-AI Summary

Coya Therapeutics (NASDAQ: COYA) has announced a leadership transition, with Arun Swaminathan Ph.D. promoted to Chief Executive Officer effective November 1, 2024. Dr. Howard Berman, the company's founder, will transition to Executive Chair of the Board. Dr. Swaminathan, who joined Coya as Chief Business Officer in April 2023, has been instrumental in executing several significant commercial transactions, including Coya's recent $700 million licensing deal with Dr. Reddy's Laboratories.

The company is preparing for the release of Alzheimer's data at the CTAD24 conference on October 29, 2024, and continues to progress COYA 302 in ALS. Coya believes Dr. Swaminathan's experience will be valuable in advancing COYA 302 in related programs such as Frontotemporal Dementia, Parkinson's Disease, and other immune-mediated diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.77%
Tags
none
Rhea-AI Summary

Coya Therapeutics (Nasdaq: COYA) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Received a $5 million investment from the Alzheimer's Drug Discovery Foundation for COYA 302 development in Frontotemporal Dementia.

2. Obtained $3.85 million from Dr. Reddy's Laboratories for COYA 302's Phase 2 ALS trial.

3. Published promising Phase 1 results for CTLA4-Ig and IL-2 combination in ALS patients.

4. Expanded research collaboration with Houston Methodist Research Institute.

5. Filed new U.S. patents for COYA 301 in combination with GLP-1 receptor agonists.

6. Q2 2024 financials: $36.6 million cash on hand, R&D expenses of $4.6 million, and net loss of $2.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.87%
Tags
-
Rhea-AI Summary

Coya Therapeutics (NASDAQ: COYA) has announced that results from a double-blind, placebo-controlled phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease will be presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid on October 29, 2024. The study, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and Alzheimer's Association, evaluated 38 patients over 30 weeks. This presentation replaces the previously announced topline data release planned for Summer 2024. A prior open-label study showed that low-dose IL-2 was well-tolerated and resulted in significant improvements in cognitive function and regulatory T cell (Treg) function and numbers in AD patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
-
Rhea-AI Summary

Coya Therapeutics (NASDAQ: COYA) has filed for intellectual property protection for the combination of COYA 301 (low-dose interleukin-2) and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs). This combination aims to enhance regulatory T cell function and may offer a multi-pathway targeted approach for treating inflammatory diseases, including neurodegenerative, autoimmune, and metabolic conditions.

The company believes this proprietary combination could lead to value-creating business development partnerships and expand the GLP-1 market beyond diabetes and obesity. Data suggests the combination may have additive and/or synergistic anti-inflammatory effects on multiple cell types. Coya is investigating these combinations to potentially bring forward an optimized novel therapeutic approach for several diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
Rhea-AI Summary

Coya Therapeutics has expanded its research collaboration with the Houston Methodist Research Institute (HMRI) to advance the development of regenerative T cell (Treg) exosome technology. This initiative is funded by the Johnson Center for Cellular Therapeutics and aims to progress towards a first-in-human clinical study. The collaboration will also focus on validating clinical biomarkers for neurodegenerative diseases and exploring drug combinations, particularly COYA 301 (low dose interleukin-2) and COYA 302 (LD IL-2 + CTLA4-Ig). These efforts could offer new therapeutic avenues for conditions like ALS, Alzheimer's, and Parkinson's Disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
none
-
Rhea-AI Summary

Coya Therapeutics has published a study in Frontiers in Neurology on an ALS treatment using a combination of CTLA4-Ig and Low Dose Interleukin-2. The treatment showed promising results in halting disease progression over 24 weeks and reducing inflammation and oxidative stress. Four participants were administered the treatment, which was well-tolerated with no serious adverse events. The study revealed an improvement or stability in ALSFRS-R scores and significant enhancement in Regulatory T cell function. The company plans to file an IND application with the FDA for a larger, randomized controlled trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.68%
Tags
none
-
Rhea-AI Summary

Coya Therapeutics (NASDAQ: COYA) announced the acceptance of a peer-reviewed manuscript in Frontiers in Neurology. The study, titled 'A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,' highlights the halting of ALS progression at six months. The therapy also showed reduced inflammation and oxidative stress, and enhanced Regulatory T cell (Treg) function. This data was previously presented at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference. Dr. Fred Grossman, Coya's Chief Medical Officer, sees this as significant validation for their approach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
Rhea-AI Summary

Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on enhancing regulatory T cell function, announced its inclusion in the MSCI USA Micro Cap Index, effective May 31, 2024. The Index, which tracks over 1,100 micro cap stocks with an average market cap of $122 million as of April 30, 2024, influences many microcap ETFs. CEO Howard Berman highlighted this inclusion as evidence of Coya's strategic focus and commitment to developing therapies for neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. Coya anticipates several key milestones throughout 2024 that could significantly impact its trajectory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
Coya Therapeutics, Inc.

Nasdaq:COYA

COYA Rankings

COYA Stock Data

87.97M
14.66M
7.03%
26.72%
1.63%
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON